This study was a single-center, single-dose, open-label study in healthy male subjects to investigate the absorption, metabolism and excretion of HRS9531 after a single subcutaneous injection of \[14C\]HRS9531.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
7
A single dose of \[14C\]HRS9531 injected subcutaneously.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Maximum concentration (Cmax).
Time frame: 0 to anticipated 64 days.
Time to reach the maximum concentration (Tmax).
Time frame: 0 to anticipated 64 days.
Half-life (t1/2).
Time frame: 0 to anticipated 64 days.
Total radioactive recovery rate in urine.
Time frame: 0 to anticipated 64 days.
Total radioactive recovery rate in feces.
Time frame: 0 to anticipated 64 days.
Cumulative radioactive recovery rate in urine.
Time frame: 0 to anticipated 64 days.
Cumulative radioactive recovery rate in feces.
Time frame: 0 to anticipated 64 days.
Whole blood total radioactivity (TRA) ratio.
Time frame: 0 to anticipated 64 days.
Plasma total radioactivity (TRA) ratio.
Time frame: 0 to anticipated 64 days.
Adverse events (AEs).
Time frame: 0 to 7 days after the last sample collection.
Serious adverse events (SAEs).
Time frame: 0 to 7 days after the last sample collection.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.